Targeted therapies in metastatic colorectal cancer |
Seong Taek Oh |
Catholic University of Korea Seoul St. Mary's Hospital |
전이성 결장직장암에서 표적치료 |
오승택 |
서울 성모병원 대장 항문외과 |
Corresponding Author:
Seong Taek Oh ,Tel: +82-2-2258-6100, Fax: +82-2-595-2822, Email: stoh@catholic.ac.kr |
Received: May 20, 2010; Accepted: June 23, 2010. |
|
Share :
|
ABSTRACT |
Treatment of colorectal cancer (CRC) has developed considerably over the past 10 years, especially in the areas of
targeted therapeutics and biomarker development. Targeted therapies, which include monoclonal antibodies and
small molecule inhibitors, directed at the vascular endothelial growth factor pathway and the epidermal growth
factor pathway are now key players in the treatment of colorectal cancer. Preclinical and clinical studies have
shown that the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid
therapeutic targets for patients with CRC.
This review focuses on the evidence supporting the current role of targeted therapy and the strategy of combining
chemotherapy and biological therapy in the treatment of metastatic colorectal cancer. |
Keywords:
metastatic colorectal cancer | targeted therapy |
|
|
|